Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China’s National Reimbursement Drug List
–the only anti-PD-1 monoclonal antibody in the NRDL for melanoma and nasopharyngeal carcinoma SHANGHAI, China, Dec. 03, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company’s product toripalimab continues to be included in Category […]